A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients

Fuente, M.J.; Sàbat, Mireia; Roca, J; Lauzurica, Ricardo; Fernández‐Figueras, María‐Teresa; Ferrándiz, Carlos

doi:10.1111/j.1365-2133.2003.05740.x

Cited by 92 publications

(105 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 The incidence of posttransplant skin cancer varies from 2% to 68%. [9][10][11][12] In the present study, incidence of skin cancers was found to be 37.3% and compatible with the literature. Advanced patient age is a common risk factor for skin tumors in transplant recipients; patients aged 102…”

Section: Discussionsupporting

confidence: 78%

“…9,12,13 Similar to the literature, the mean age of our patients with skin cancers was 48.9 ± 12.2 years, and it is significantly higher than that of patients who developed other malignant tumors. The development of skin SCC was reported more frequently than BCC in kidney transplant recipients.…”

Section: Eda Yılmaz Akçay Et Al/experimental and Clinical Transplantasupporting

confidence: 74%

“…32 Advanced patient age was reported to be a conventional risk factor for posttransplant malignancies, particularly for SCC. 9,37 At the time of tumor diagnosis, the patients with solid-organ tumors were older than those with KS and PTLD, but they were nearly the same age as the skin tumor group patients in our study. Apel and associates showed similar findings in which they found skin and nonskin solid organ tumors at the same age.…”

Section: Eda Yılmaz Akçay Et Al/experimental and Clinical Transplantamentioning

confidence: 58%

“…In contrast, some other studies showed higher ratios of BCC to SCC. 9,11 Some cancers that are uncommon in general populations have a tendency to develop in organ transplant recipients. One of these uncommon neoplasms is KS.…”

Section: Eda Yılmaz Akçay Et Al/experimental and Clinical Transplantamentioning

confidence: 99%

See 3 more Smart Citations

Untitled

Akçay

Tepeoğlu²,

Özdemir³

et al. 2016

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: The aim of this study was to evaluate the incidence of posttransplant malignancy in kidney transplant patients and investigate the clinical and histopathologic features of these patients. Materials and Methods: We retrospectively reviewed information on donor and recipient characteristics, patient and graft survival, and cancer incidence after transplant for 867 kidney transplant patients. Patients with neoplasms prior to transplant were excluded. A follow-up study estimated cancer incidence after transplant. Results: Neoplasms were diagnosed in 59 patients (6.8%), 41 men and 18 women; 22 (37.3%) had skin tumors, 19 (32.2%) had solid tumors, 10 (16.9%) had posttransplant lymphoproliferative disorders, and 8 (13.6%) had Kaposi sarcoma. The mean age at the time of malignant tumor diagnosis was 42.7 ± 13.6 years, and statistically significant differences were found between tumor groups (P < .01). The average latency period between transplant and diagnosis of malignant tumors was 99.8 ± 56.9 months for solid tumors, 78.4 ± 52 months for skin tumors, 64.5 ± 48.8 months for posttransplant lymphoproliferative disorders, and 13.5 ± 8.8 months for Kaposi sarcoma, with significant difference found between tumor groups (P < .01). Ten patients (16.9%) had more than 1 malignant tumor. Eighteen patients died, with a mean time to death of 31.5 ± 22.8 months after tumor diagnosis. A significant positive association was found between survival and the number of tumors (P = .001); 5-year survival after tumor diagnosis was 81% and 40% for patients with 1 malignant tumor and patients with more than 1 malignant tumor, respectively. Conclusions:Malignancy is a common cause of death after renal transplant. Early detection and treatment of posttransplant malignancies is an important challenge. Screening these patients for malignancies posttransplant is crucial, and efforts should be directed to define effective immunosuppressive protocols that are associated with a lower incidence of malignancy.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Eda Yılmaz Akçay Et Al/experimental and Clinical Transplantasupporting

confidence: 74%

Section: Eda Yılmaz Akçay Et Al/experimental and Clinical Transplantamentioning

confidence: 58%

Section: Eda Yılmaz Akçay Et Al/experimental and Clinical Transplantamentioning

confidence: 99%

See 2 more Smart Citations

Untitled

Akçay

Tepeoğlu²,

Özdemir³

et al. 2016

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…An incidence rate about 2.3-3.1% has been reported for organ-transplant related malignancies [8,9]. The most common malignancy observed in solid organ transplant recipients is non-melanoma skin cancer (NMSC) [10][11][12] and particularly in squamous cell carcinoma (relative risk 14-82) [13,14]. Many etiologic factors such as ultraviolet radiation, human papillomavirus infection, genetics and immunosuppressive therapy play an important role in the occurrence of post-transplant NMSC [15,16].…”

Section: Introductionmentioning

confidence: 99%

Are We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years’ Experience

et al. 2016

View full text Add to dashboard Cite

Objective: Our aim is to evaluate the frequency and characteristics of cancer in the population of patients with solid organ transplant who are under immunosuppressive medication. In this study we aimed to emphasize the importance of early diagnosis of cancer in solid organ transplant recipients. An aging population began to receive solid organ transplantation and survival times prolonged. But this had a cost and new problems came forward. Especially de novo cancers because of immunosuppressive therapy took notice. Risk of malignancy increases after organ transplantation and cancer incidence was about 2.3-3.1% in these patients including skin cancer, lung cancer, malign lymphoma, cervix cancer, kaposi sarcoma, and hepatobiliary cancer. Materials and Methods:The files of 328 organ transplant recipients followed from January 2004 to April 2015 at Atatürk University Medical Faculty were retrospectively reviewed.Results: Eight patients developed cancer (2.4%). There were six males and two females. Age at cancer diagnosis ranged from 42 to 79 years old with average of 55 years. The interval from solid organ transplantation to cancer diagnosis ranged from 6 months to 30 years. Among the patients, five were renal transplant recipients and two were liver transplant recipients. Four patients had stage IV disease, one patient stage IIIB, and three patients had stage I disease. For none of the patients a diagnosis with screening methods was used for cancer before any complaints of tumor emerged. Conclusion:To diagnose cancer at early stages in solid organ transplant recipients, earlier and detailed cancer screening is very important. The association between diagnosis of cancer at early stages and prolonged overall survival time is well known. Detailed and careful evaluation for occult malignancies in pre-transplantation period is also important. Keywords: Cancer, immunosuppression, screening, transplantation ÖzAmaç: Amacımız solid organ transplantı olan, immunsupresif tedavi altındaki hastalarda gelişen kanser sıklığını ve özelliklerini değerlendirmektir. Bu çalışmada, solid organ transplant alıcıla-rında gelişen kanserlerin erken tanısının önemini vurgulamayı amaçladık. Yaşlanan nüfusla birlikte artan solid organ transplantı ile hayatta kalma süreleri uzamıştır. Fakat bu durum yeni maliyetler getirmiş ve yeni sorunlara neden olmuştur. Özellikle immunsupresif tedavilerin sonucunda de novo kanserler görülme-ye başlamıştır. Organ nakli sonrası kanser riski artar ve en sık cilt kanseri, akciğer kanseri, malign lenfoma, serviks kanseri, kaposi sarkomu ve hepatobilier kanseri içeren bu grupta insidans %2,3-3,1'dir. Sonuç: Solid organ transplant alıcılarında erken evrede kanser tanısı için ayrıntılı ve erken kanser taraması çok önemlidir. Erken tanı ve tedavi ile uzun süreli genel sağkalım arasındaki ilişki iyi bilinmektedir. Nakil öncesi dönemde okült maligniteler için detaylı ve dikkatli bir değerlendirme de önemlidir. Gereç ve

show abstract